Cargando…
Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries. Psoriasis is associated with limited quality of life, cardiovascular disease, and depression. The approval of injectable biological agents has revolutionized the management of moderate to severe ps...
Autores principales: | Schmitt, Jochen, Wozel, Gottfried |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726069/ https://www.ncbi.nlm.nih.gov/pubmed/19707417 |
Ejemplares similares
-
Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023) -
Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008) -
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
por: Moore, Angela Y, et al.
Publicado: (2010) -
Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007) -
Guillain-Barré syndrome in a patient on adalimumab for the
treatment of psoriasis
por: de Natividade, Natallia Barreiros, et al.
Publicado: (2017)